Business
Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results
Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Michael K. McGarrity, CEO o
About this update from Mdxhealth Sa
[{"type":"image","alt":"mdxhealth","displaySize":"","headline":null,"caption":"mdxhealth","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/4984d0922515a173e18d6d7a99b017cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sf2Nm0vg.EDhfYYAQ2giIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4984d0922515a173e18d6d7a99b017cc","width":300,"height":44}},"lazy":false},{"type":"text","content":"Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET","length":212,"tagName":"p"},{"type":"text","content":"IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024.","length":286,"tagName":"p"},{"type":"text","content":"Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report another strong quarter and a successful year for mdxhealth, driven by consistent execution and robust demand for our precision diagnostics. Our performance in Q4 underscores our commitment to deliver sustainable growth and puts us on track to achieve adjusted EBITDA profitability in the first half of this year. We continue to see strong adoption of our expanded menu of tests, and our commercial team is driving further penetration into our key urology market. With the pending draw of the second tranche under our OrbiMed debt facility, our balance sheet will be significantly strengthened to meet our 2025 earnout obligation to Exact Sciences as well as support the execution of our 2025 business plan. We are confident in our ability to deliver continued growth and deliver value to our stakeholders, including patients, customers and shareholders.”","length":931,"tagName":"p"},{"type":"text","content":"Key Highlights:","length":15,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"2024 revenue of $90.0 million, an increase of 28% over 2023","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourth quarter revenue of $24.7 million, a...